On to the moon or curtains

If BNC210 for PTSD hits stat sig on primary end point, it will be a sweet ride to at least $1. If not and they resort to subgroup analysis, back to 10 cents per share in a blink. I have owned this stock for more than 10 years. Payback or write-off on Tuesday.

It is kind of sad that the company could not proceed to a single phase-3 trial after all these years. So much hype and nothing to show for. Good luck to all of us!